Breaking News

Trilantic Capital Partners Europe Acquires Italian CDMO

Doppel Farmaceutici is active in pharmaceutical research, development, formulation, manufacturing and packaging

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Trilantic Capital Partners Europe, a private equity firm focused on mid-market transactions in Europe, has completed the acquisition of a 90% shareholding in Doppel Farmaceutici. Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a contract development and manufacturing organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters